DDInter980 DDInter1628
Isavuconazonium is a second-generation triazole antifungal approved on March 6, 2015 by the FDA and July 2015 by the EMA for the treatment of adults with invasive aspergillosis and invasive mucormycosis, marketed by Astellas under the brand Cresemba. It is the prodrug form of isavuconazole, the active moiety, and it is available in oral and parenteral formulations. Due to low solubility in water of isavuconazole on its own, the isovuconazonium formulation is favorable as it has high solubility in water and allows for intravenous administration. This formulation also avoids the use of a cyclodextrin vehicle for solubilization required for intravenous administration of other antifungals such as voriconazole and posaconazole, eliminating concerns of nephrotoxicity associated with cyclodextrin. Isovuconazonium has excellent
Ruxolitinib, formerly known as INCB018424 or INC424, is an anticancer drug and a Janus kinase (JAK) inhibitor. It is a potent and selective inhibitor of JAK1 and JAK2, which are tyrosine kinases involved in cytokine signalling and hematopoiesis. Myeloproliferative neoplasms, such as myelofibrosis and polycythemia vera, are often characterized by aberrant activation of the JAK-STAT pathway, leading to abnormal blood cell counts and thrombotic complications. By inhibiting JAK1 and JAK2, ruxolitinib works to block the dysregulated cell signalling pathways and prevents abnormal blood cell proliferation. Due to a large number of patients with myeloproliferative neoplasms who have JAK2 mutations, ruxolitinib was the first ATP-competitive inhibitor of JAK1 and JAK2 ever developed. Ruxolitinib was first approved for the treatment of adult patients with myelofibrosis by the FDA in 2011, followed by EMA's approval in 2012. In 2014, it was approved for the treatment of polycythemia vera in adults who have an inadequate response to or are intolerant of [hydroxyurea] and in 2019, ruxolitinib was approved for use in steroid-refractory acute graft-versus-host disease in adults and children. The topical formulation of ruxolitinib is used to treat atopic dermatitis and vitiligo. It is being investigated for other inflammatory skin conditions. Ruxolitinib has been investigated to treat patients with coronavirus disease 2019 (COVID-19) accompanied by severe systemic hyperinflammation. In phase II clinical trials, ruxolitinib improved chest computed tomography and improved recovery in patients with lymphopenia.[A229713, A229718] However, phase III clinical trials later determined that ruxolitinib was inadequate in meeting its primary endpoint of reducing the number of hospitalized COVID-19 patients who experienced severe complications thus the drug was not approved as a treatment for COVID-19.
Isavuconazonium {u} may cause a minor interaction that can limit clinical effects when taken with {v} Sibutramine
Sibutramine {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Ruxolitinib
Isavuconazonium {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Loratadine
Loratadine {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Ruxolitinib
Isavuconazonium {u} may cause a minor interaction that can limit clinical effects when taken with {v} Sibutramine
Sibutramine {u} (Compound) causes {v} (Side Effect) Anaemia
Anaemia {u} (Side Effect) is caused by {v} (Compound) Ruxolitinib
Isavuconazonium {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Imatinib
Imatinib {u} (Compound) treats {v} (Disease) hematologic cancer
hematologic cancer {u} (Disease) is treated by {v} (Compound) Ruxolitinib
Isavuconazonium {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Loratadine
Loratadine {u} (Compound) causes {v} (Side Effect) Fatigue
Fatigue {u} (Side Effect) is caused by {v} (Compound) Ruxolitinib
Isavuconazonium {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Imatinib
Imatinib {u} (Compound) downregulates {v} (Gene) NPDC1
NPDC1 {u} (Gene) is downregulated by {v} (Compound) Ruxolitinib
Isavuconazonium {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Astemizole
Astemizole {u} (Compound) upregulates {v} (Gene) HMGCR
HMGCR {u} (Gene) is upregulated by {v} (Compound) Ruxolitinib
Isavuconazonium {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Astemizole
Astemizole {u} (Compound) upregulates {v} (Gene) SLC2A6
SLC2A6 {u} (Gene) is downregulated by {v} (Compound) Ruxolitinib
Isavuconazonium {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Crizotinib
Crizotinib {u} (Compound) binds {v} (Gene) DCLK1
DCLK1 {u} (Gene) is bound by {v} (Compound) Ruxolitinib
Isavuconazonium {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Pazopanib
Pazopanib {u} (Compound) binds {v} (Gene) RIOK2
RIOK2 {u} (Gene) is upregulated by {v} (Compound) Ruxolitinib
Isavuconazonium may cause a minor interaction that can limit clinical effects when taken with Sibutramine and Sibutramine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Ruxolitinib (Compound)
Isavuconazonium may cause a moderate interaction that could exacerbate diseases when taken with Loratadine and Loratadine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Ruxolitinib (Compound)
Isavuconazonium may cause a minor interaction that can limit clinical effects when taken with Sibutramine and Sibutramine (Compound) causes Anaemia (Side Effect) and Anaemia (Side Effect) is caused by Ruxolitinib (Compound)
Isavuconazonium may cause a moderate interaction that could exacerbate diseases when taken with Imatinib and Imatinib (Compound) treats hematologic cancer (Disease) and hematologic cancer (Disease) is treated by Ruxolitinib (Compound)
Isavuconazonium may cause a moderate interaction that could exacerbate diseases when taken with Loratadine and Loratadine (Compound) causes Fatigue (Side Effect) and Fatigue (Side Effect) is caused by Ruxolitinib (Compound)
Isavuconazonium may cause a moderate interaction that could exacerbate diseases when taken with Imatinib and Imatinib (Compound) downregulates NPDC1 (Gene) and NPDC1 (Gene) is downregulated by Ruxolitinib (Compound)
Isavuconazonium may cause a moderate interaction that could exacerbate diseases when taken with Astemizole and Astemizole (Compound) upregulates HMGCR (Gene) and HMGCR (Gene) is upregulated by Ruxolitinib (Compound)
Isavuconazonium may cause a moderate interaction that could exacerbate diseases when taken with Astemizole and Astemizole (Compound) upregulates SLC2A6 (Gene) and SLC2A6 (Gene) is downregulated by Ruxolitinib (Compound)
Isavuconazonium may cause a moderate interaction that could exacerbate diseases when taken with Crizotinib and Crizotinib (Compound) binds DCLK1 (Gene) and DCLK1 (Gene) is bound by Ruxolitinib (Compound)
Isavuconazonium may cause a moderate interaction that could exacerbate diseases when taken with Pazopanib and Pazopanib (Compound) binds RIOK2 (Gene) and RIOK2 (Gene) is upregulated by Ruxolitinib (Compound)